Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Banco de datos
Tipo del documento
Publication year range
1.
J Pharm Pharmacol ; 71(5): 849-859, 2019 May.
Artículo en Inglés | MEDLINE | ID: mdl-30652314

RESUMEN

OBJECTIVES: Epiisopiloturine (EPI) and epiisopilosine (EPIIS) are side products in the pharmaceutical industry. The present study aimed to investigate the anti-inflammatory potential of the alkaloids EPI and EPIIS in human neutrophils and mechanical hyperalgesia in mice. METHODS: Neutrophils (5 × 106  cells/ml) incubated with EPI and EPIIS and stimulated by the addition of N-formyl-methionyl-leucyl-phenylalanine or phorbol 12-myristate-13-acetate. The release of myeloperoxidase (MPO), reactive oxygen species (ROS) production, calcium influx, gene expression of NF-κB and pro-inflammatory cytokines production were evaluated. It was also investigated the effect these alkaloids on carrageenan-induced mechanical hyperalgesia model in mice. KEY FINDINGS: We demonstrated that both EPI and EPIIS inhibited the degranulation of activated neutrophils. This effect was accompanied by the reduction in ROS, the prevention of the increase in intracellular Ca2+ and decrease in the density of cytosolic NF-κB, and inhibition of TNF-α and IL-6 production. Evaluating hypernociception in mice, EPI and EPIIS inhibited carrageenan-induced inflammatory hypernociception and reduced MPO levels. CONCLUSIONS: The results obtained suggest EPI and EPIIS not only inhibit neutrophils functions in vitro, but also exhibits anti-inflammatory properties in vivo, acting through the modulation of the activation and/or accumulation of neutrophils in the inflammatory focus. Thus, EPI and EPIIS possess promising anti-inflammatory therapeutic potential.


Asunto(s)
4-Butirolactona/análogos & derivados , Alcaloides/farmacología , Antiinflamatorios/farmacología , Imidazoles/farmacología , Neutrófilos/efectos de los fármacos , 4-Butirolactona/farmacología , Animales , Calcio/metabolismo , Humanos , Hiperalgesia/metabolismo , Interleucina-6/metabolismo , Masculino , Ratones , N-Formilmetionina Leucil-Fenilalanina , FN-kappa B/metabolismo , Neutrófilos/metabolismo , Peroxidasa/efectos de los fármacos , Peroxidasa/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Acetato de Tetradecanoilforbol , Factor de Necrosis Tumoral alfa/metabolismo
2.
Biomed Pharmacother ; 102: 278-285, 2018 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-29567541

RESUMEN

Epiisopiloturine (EPI) is an important imidazole alkaloid because of its pharmacological properties. The aim of this study was to investigate the effects of epiisopiloturine on inflammatory parameters of the colonic mucosa in a rat model of Crohn's disease (CD). For this, we induced colitis using trinitrobenzenosulfonic acid and determined myeloperoxidase (MPO), interleukin 1 ß (IL-1ß), glutathione (GSH), and malondialdehyde (MDA) levels in the intestinal mucosa. The location and expression of the inflammatory markers in the colon were investigated by immunohistochemistry for NO synthase induced (iNOS), interleukin 1 beta (IL-1ß), and cyclooxygenase-2 (COX-2) and western blotting (iNOS and COX-2), respectively. Compared with TNBS alone, epiisopiloturine at 1 mg/kg reduced the macroscopic and microscopic scores, wet weight of the colon, and neutrophilic infiltration and expression of the pro-inflammatory cytokine IL-1ß. Epiisopiloturine at 1 mg/kg maintained or restored GSH levels and simultaneously decreased MDA levels. Animals treated with epiisopiloturine exhibited reduced immunostaining for IL-1ß, iNOS, and COX-2 and reduced cell count per field. Epiisopiloturine reduced the expression of COX-2 and iNOS in the colon. Based on these findings, we conclude that epiisopiloturine at 1 mg/kg may be an important pharmacological tool against intestinal inflammatory diseases due to its inhibitory action on key enzymes and products involved in inflammation.


Asunto(s)
4-Butirolactona/análogos & derivados , Alcaloides/uso terapéutico , Antiinflamatorios/uso terapéutico , Enfermedad de Crohn/tratamiento farmacológico , Imidazoles/uso terapéutico , Peroxidación de Lípido/efectos de los fármacos , 4-Butirolactona/farmacología , 4-Butirolactona/uso terapéutico , Alcaloides/farmacología , Animales , Antiinflamatorios/farmacología , Enfermedad de Crohn/inmunología , Modelos Animales de Enfermedad , Femenino , Imidazoles/farmacología , Inflamación , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/inmunología , Ratas Wistar , Ácido Trinitrobencenosulfónico
3.
Biomed Pharmacother ; 87: 188-195, 2017 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-28056423

RESUMEN

OBJECTIVE: This study aimed to investigate the protective effect of epiisopiloturine hydrochloride (EPI), an imidazole alkaloid, on NAP-induced gastrointestinal damage in rats. METHODS: Initially, rats were pretreated with 0.5% carboxymethylcellulose (vehicle) or EPI (3, 10 and 30mg/kg, p.o. or i.p., groups 3-5, respectively) twice daily, for 2days. After 1h, NAP (80mg/kg, p.o.) was given. The control group received only vehicle (group 1) or vehicle+naproxen (group 2). Rats were euthanized on 2nd day, 4h after NAP treatment. Stomachs lesions were measured. Samples were collected for histological evaluation and glutathione (GSH), malonyldialdehyde (MDA), myeloperoxidase (MPO), and cytokines levels. Moreover, gastric mucosal blood flow (GMBF) was evaluated. RESULTS: EPI pretreatment prevented NAP-induced macro and microscopic gastric damage with a maximal effect at 10mg/kg. Histological analysis revealed that EPI decreased scores of damage caused by NAP. EPI reduced MPO (3.4±0.3U/mg of gastric tissue) and inhibited changes in MDA (70.4±8.3mg/g of gastric tissue) and GSH (246.2±26.4mg/g of gastric tissue). NAP increased TNF-α levels, and this effect was reduced by EPI pretreatment. Furthermore, EPI increased GMBF by 15% compared with the control group. CONCLUSION: Our data show that EPI protects against NAP-induced gastric and intestinal damage by reducing pro-inflammatory cytokines, reducing oxidative stress, and increasing GMBF.


Asunto(s)
4-Butirolactona/análogos & derivados , Alcaloides/uso terapéutico , Enfermedades Gastrointestinales/prevención & control , Imidazoles/uso terapéutico , Naproxeno/toxicidad , Pilocarpus , Extractos Vegetales/farmacología , 4-Butirolactona/aislamiento & purificación , 4-Butirolactona/farmacología , 4-Butirolactona/uso terapéutico , Alcaloides/aislamiento & purificación , Alcaloides/farmacología , Animales , Relación Dosis-Respuesta a Droga , Mucosa Gástrica/efectos de los fármacos , Mucosa Gástrica/patología , Enfermedades Gastrointestinales/inducido químicamente , Enfermedades Gastrointestinales/patología , Imidazoles/aislamiento & purificación , Imidazoles/farmacología , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/patología , Masculino , Extractos Vegetales/aislamiento & purificación , Hojas de la Planta , Sustancias Protectoras/aislamiento & purificación , Sustancias Protectoras/farmacología , Ratas , Ratas Wistar
4.
Biomed Pharmacother ; 88: 488-499, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-28126674

RESUMEN

Schistosomiasis is a world health problem, and praziquantel is the only drug currently used for the treatment. There is some evidence that extensive monotherapy of praziquantel may be leading to drug resistance in the parasite. In order to find alternative treatments, the effects of the combination of epiisopiloturine (EPI), piplartine (PPT) and praziquantel (PZQ) were evaluated. Similarity analysis of these compounds was performed using optimized molecular structures to compare the shape and the charge modeling of combinations between PZQ and EPI or PPT. Supported by this data, in vitro association of PZQ-PPT, PZQ-EPI, and EPI-PPT was carried out, and the activity of these combinations against Schistosoma mansoni was assessed. The results showed synergistic activity with a combination index (CI) of 0.42 for the treatment with PZQ-PPT. Both PZQ-EPI and EPI-PPT combinations also showed synergistic effects, with CI values of 0.86 and 0.61, respectively. Surface alterations in the tegument of adult schistosomes after the treatments were observed using laser confocal microscopy and scanning electron microscopy. Additionally, the association of EPI-PPT decreased the cytotoxicity when compared with both isolated compounds in three different lines of mammalian cells. Thus, synergistic combinations of PZQ-PPT, PZQ-EPI, and EPI-PPT create the possibility of reduced doses to be used against Schistosoma mansoni.


Asunto(s)
4-Butirolactona/análogos & derivados , Imidazoles/farmacología , Piperidonas/farmacología , Praziquantel/farmacología , Schistosoma mansoni/efectos de los fármacos , 4-Butirolactona/química , 4-Butirolactona/farmacología , Animales , Antiprotozoarios/farmacología , Forma de la Célula/efectos de los fármacos , Chlorocebus aethiops , Cricetinae , Perros , Sinergismo Farmacológico , Quimioterapia Combinada , Imidazoles/química , Células de Riñón Canino Madin Darby , Masculino , Ratones , Microscopía Confocal , Piperidonas/química , Praziquantel/química , Schistosoma mansoni/ultraestructura , Células Vero
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda